Home/Filings/4/0001209191-18-002599
4//SEC Filing

Vanover Kimberly E. 4

Accession 0001209191-18-002599

CIK 0001567514other

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 8:14 PM ET

Size

18.4 KB

Accession

0001209191-18-002599

Insider Transaction Report

Form 4
Period: 2018-01-03
Vanover Kimberly E.
VP, Clinical Development
Transactions
  • Exercise/Conversion

    Common Stock

    2018-01-03+2,64812,776 total
  • Exercise/Conversion

    Common Stock

    2018-01-04+1,55414,330 total
  • Sale

    Common Stock

    2018-01-05$17.37/sh1,185$20,58313,145 total
  • Exercise/Conversion

    Restricted Stock Units

    2018-01-032,6485,298 total
    Common Stock (2,648 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2018-01-041,5541,554 total
    Common Stock (1,554 underlying)
  • Award

    Restricted Stock Units

    2018-01-03+48,48048,480 total
    Common Stock (48,480 underlying)
  • Award

    Stock Option (right to buy)

    2018-01-03+65,16465,164 total
    Exercise: $15.47Exp: 2028-01-03Common Stock (65,164 underlying)
Footnotes (8)
  • [F1]Restricted stock units convert into common stock on a one-for-one basis.
  • [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.97 to $17.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
  • [F4]Each restricted stock unit represents a contingent right to receive one share of common stock.
  • [F5]On January 3, 2017, the reporting person was granted 7,946 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
  • [F6]On January 4, 2016, the reporting person was granted 4,661 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
  • [F7]On January 3, 2018, the reporting person was granted options to purchase 65,164 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
  • [F8]On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Issuer

Intra-Cellular Therapies, Inc.

CIK 0001567514

Entity typeother

Related Parties

1
  • filerCIK 0001585669

Filing Metadata

Form type
4
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:14 PM ET
Size
18.4 KB